Ascletis Pharma (HKG:1672) said it presented key preclinical data for its ASC36_35FDC in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan, Italy.
The data showed promising activity in body‑weight reduction, appetite suppression, formulation stability and pharmacokinetic properties, the filing said.
The conference began Sept. 28 and will conclude Oct. 2.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.